AAM Welcomes US Access Bill
Bipartisan Legislation Would Exempt Low-Cost Drugs From Medicaid Penalty
The AAM has backed the draft Protecting Access to Affordable Medicines Act of 2020 introduced by the US House of Representatives members GK Butterfield, Billy Long and Tony Cardenas and has urged House members to co-sponsor the bill, which aims to protect low-cost generic medicines from a “misguided” Medicaid penalty.
You may also be interested in...
The AAM has applauded US proposals to lower drug prices, following the development of the HHS’s 45-day plan in response to president Joe Biden’s executive order on promoting competition. However, AAM chief executive Dan Leonard has criticized Congressional proposals to weaken the 180-day incentive for first generics and curtail patent settlement agreements as “misguided.”
The AAM has unveiled its policy priorities for sustainable access to generics and biosimilars for the newly elected US president Joe Biden’s administration and the 117th Congress. The association has also launched a new advocacy campaign called “Secure Our Meds,” kicking off with a report on “Securing Sustainable Markets.”
Laying out the 2021 outlook for US generics and biosimilars, AAM president and CEO Dan Leonard has urged US president-elect Joe Biden and lawmakers in the US Congress to act to maximize savings and access to medicines.